Gene test may spare melanoma patients unnecessary surgery

NCT ID NCT04759781

Ongoing Knowledge-focused Sponsor: SkylineDx Source: ClinicalTrials.gov ↗

First seen Apr 29, 2026 · Last updated May 18, 2026 · Updated 2 times

Summary

This study is testing a new gene test (Merlin Assay) to see if it can accurately predict whether melanoma has spread to nearby lymph nodes in newly diagnosed patients. About 1,820 adults with melanoma who are scheduled for a sentinel lymph node biopsy will provide tumor samples for the test. The goal is to improve staging and potentially avoid unnecessary biopsies in low-risk patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Duke University

Durham, North Carolina, 27705, United States
Emory University School of Medicine

Atlanta, Georgia, 30322, United States
Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States
Mayo Clinic

Rochester, Minnesota, 55905, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Moffitt Cancer Center

Tampa, Florida, 33612, United States
University of Kentucky

Lexington, Kentucky, 40506, United States
University of Louisville

Louisville, Kentucky, 40292, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States

Conditions

Explore the condition pages connected to this study.

MELANOMA